Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFL-PDT Depth for Actinic Keratosis
NCT03325803Phase 1Completed
- Sponsor
- Dong-A University
- Start
- Sep 2015
- Primary completion
- Sep 2016
- Modality
- Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised trial of methyl aminolevulinate in actinic keratosis (AK) (3 arms), sponsored by Dong-A University. Primary endpoints: Short-term complete response rates at 3 months, Long-term complete response rates at 12 months and 2 more. Started Sep 2015; status: completed.
02
Drugs
methyl aminolevulinate
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT03325803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03325803.